deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01535157

Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma

Sponsor: South Plains Oncology Consortium

Conditions Cancer of Ovary Cancer of the Ovary Ovarian Cancer Ovary Neoplasms Primary Peritoneal Carcinoma
Interventions Fenretinide/LXS + Ketoconazole
Updated 10 times since 2017 Last updated: Aug 25, 2020 Started: Feb 29, 2012 Primary completion: Jun 30, 2017 Completion: Jun 30, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

drug combination not providing any efficacy. Will use this data in opening new trial

Other terminated trials from South Plains Oncology Consortium

More terminations from South Plains Oncology Consortium

This PHASE1/PHASE2 trial investigates Cancer of Ovary and Cancer of the Ovary and is currently terminated or withdrawn. South Plains Oncology Consortium leads this study, which shows 10 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshotRecruiting~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Aug 2019 · 14 months · monthly snapshotActive Not Recruiting~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshotUnknown Status~Oct 2019 – ~Sep 2020 · 11 months · monthly snapshotCompleted~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Sep 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

    Status: Completed → Terminated

  5. Oct 2019 — Sep 2020 [monthly]

    Completed PHASE1_PHASE2

    Status: Unknown Status → Completed

▶ Show 5 earlier versions

  1. Aug 2019 — Oct 2019 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Active Not Recruiting → Unknown Status

  2. Jun 2018 — Aug 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Sep 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Feb 2017 — Sep 2017 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Feb 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • South Plains Oncology Consortium
Data source: South Plains Oncology Consortium

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations